Lorcaserin in obesity: minimal benefits and ill-defined harms-Reference-Cited by-同舟云学术

Lorcaserin in obesity: minimal benefits and ill-defined harms

Published:2019-01-30 Issue:4 Volume:24 Page:145-146
ISSN:2515-446X
Container-title:BMJ Evidence-Based Medicine
language:en
Short-container-title:BMJ EBM

Author:

Onakpoya Igho J^ORCID,Aronson Jeffrey K

Publisher

BMJ

Subject

General Medicine

Reference7 articles.

1. Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients

2. Post-marketing withdrawal of anti-obesity medicinal products because of adverse drug reactions: a systematic review;Onakpoya;BMC Med,2016

3. FDA Approval of Obesity Drugs

4. European Medicines Agency. Withdrawal of the marketing authorisation application for Belviq (lorcaserin). http://www.ema.europa.eu/docs/en_GB/document_library/Medicine_QA/2013/05/WC500143811.pdf (accessed 02 Sep 2018).

5. Benefits and harms in pivotal trials of oral centrally acting antiobesity medicines: a systematic review and meta-analysis;Onakpoya;Obesity,2018

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect on Weight Loss of an Oral Supplement Containing Cinnamon Bark (Cinnamomum cassia) and Withania somnifera in Adult Patients with Overweight and Obesity: A Pilot Study;J;2023-09-02

2. When I use a word . . . Commercial clinical trials;BMJ;2023-05-30

3. Is lorcaserin really associated with increased risk of cancer? A systematic review and meta‐analysis;Obesity Reviews;2020-12

4. Transnasal Delivery of the Peptide Agonist Specific to Neuromedin-U Receptor 2 to the Brain for the Treatment of Obesity;Molecular Pharmaceutics;2019-11-25

5. Why reports of clinical trials should include updated meta-analyses;BMJ Evidence-Based Medicine;2019-08-31